Brief: Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial for the Treatment of Soft Tissue Sarcomas Lung Metastases

Moleculin Biotech

06/11/2023 13:41

Nov 6 (Reuters) - Moleculin Biotech Inc  MBRX.O :
    * MOLECULIN PRESENTS POSITIVE PRELIMINARY EFFICACY FINDINGS
FROM
PHASE 1B/2 CLINICAL TRIAL DEMONSTRATING 64% STABLE DISEASE RATE
THROUGH TWO CYCLES OF ANNAMYCIN FOR THE TREATMENT OF SOFT TISSUE
SARCOMAS (STS) LUNG METASTASES
    * MOLECULIN BIOTECH INC - ANNAMYCIN CONTINUES TO BE 100%
NON-CARDIOTOXIC

Source text for Eikon:  ID:nPn2w35KJa 
Further company coverage:  MBRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))